RISK OF DEATH AND COPD HOSPITALIZATION WITH FLUTICASONE FUROATE-CONTAINING THERAPY: POST HOC SUBGROUP ANALYSIS FROM THE SUMMIT TRIAL IN PATIENTS WITH COPD AND A HISTORY OF EXACERBATION